



VGX CEO named Among 50 Most Influential Men under 42

Blue Bell, PA – September 22, 2006 –

J. Joseph Kim, Ph.D., Co-founder, President & CEO of VGX Pharmaceuticals, has placed number 27 on a list of the "50 Most Influential Men Under 42" in the October "Power Issue" of Details, a trendy, upscale magazine catering to the contemporary male. This is the second time that Dr. Kim has been named to this select group of business and political leaders as well as entertainers and other influential men by Details. In October 2003, Dr. Kim was ranked number 38 on the same list.

This year's ranking was led by Actors Brad Pitt and Vince Vaughn, followed by Chad Hurley and Steve Chen, the co-founders of entertainment company YouTube. Other influential men include No. 20, Shawn Carter (A.K.A. Jay-Z), 36, President & CEO of Def Jam Recordings; No. 25, Bashar Al-Assad, 41, President of Syria; No. 31, Dan Bartlett, 35, White House Counselor; No. 33, Ryan Seacrest, 31, Host, American Idol.

The Google Co-founders Sergei Brin and Larry Page, No. 11, are joined by Dov Charney, No. 32, founder and CEO of American Apparel; David Lauren, No. 21, Sr. VP of Polo Ralph Lauren; Ryan Kavanaugh No. 26, CEO of Relativity Media; NBA Stars LeBron James and Dwayne Wade, No. 35, and US Senator John Sununu, No. 44.

Entertainers Leonardo DiCaprio, No. 9; Stephen Colbert, No. 12; Nick Lachey, No. 28; and Kanye West, No. 42; Kiefer Sutherland, No. 45; Dane Cook, No. 50, also made the list.

"I am flattered to be included in this select group of people again. I hope to continue to improve with age," said Dr. Kim.

A co-founder of VGX Pharmaceuticals, Dr. Kim is a veteran of biopharmaceutical industry. Prior to VGX, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck. These products include FDA-approved vaccines for Hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim has published over 70 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels. Dr. Kim has garnered many honors during his career. In 2002, Dr. Kim was named as one of the world's top 100 young innovators by Technology Review magazine. Also in 2002, Dr. Kim was chosen as one the "40 under 40" by the Philadelphia Business Journal as one of the 40 most dynamic professionals who are under 40 years of age in the region. In 2004, Dr. Kim and VGX Pharmaceuticals were selected as one of 30 Technology Pioneers by the World Economic Forum. Furthermore, Dr. Kim was featured in the "Who's Next 2005" issue of Newsweek International, which included a group of 10 leaders, scientists, and executives at the forefront of change and impact in the world. Most recently in 2006, Dr. Kim has been named a Young Global Leader by the Forum of Young Global Leaders, an affiliate of the World Economic Forum. Dr. Kim was among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries. Dr. Kim has also been featured in articles in Forbes and the New Yorker.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2007 for the Company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com